BK IMMO

{
  "notary": {
    "name": "Kim LAGAE",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2025-02-24",
    "filing_date": "2025-02-20",
    "act_kind_objet": "STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS), DENOMINATION"
  },
  "decision": {
    "body": "enig_aandeelhouder_schriftelijk",
    "act_date": "2025-02-10",
    "unanimous": true
  },
  "statute_change": {
    "kinds": [
      "translation",
      "coordination",
      "full_restatement",
      "targeted_amendment",
      "name_change",
      "object_change"
    ],
    "scope": "full_restatement",
    "trigger": "other",
    "language_after": "fr",
    "language_before": "fr"
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0756.915.546",
    "name_full_after": "BK IMMO",
    "legal_form_after": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
    "name_full_before": "PHARMA AND BIOTECH LEADING CONSULT",
    "current_zetel_raw": "Place Philippe Werrie 24 1090 Jette",
    "legal_form_before": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
  },
  "special_mandates": [],
  "articles_modified": [
    {
      "summary": "L\u0027article 1 des statuts a \u00E9t\u00E9 remplac\u00E9 par un texte d\u00E9finissant la soci\u00E9t\u00E9 comme une soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e nomm\u00E9e \u00AB BK IMMO \u00BB.",
      "new_text": "La soci\u00E9t\u00E9 rev\u00EAt la forme d\u0027une soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e.\nElle est d\u00E9nomm\u00E9e \u00AB BK IMMO \u00BB.",
      "change_kind": "replaced",
      "article_title": null,
      "article_number": "1"
    },
    {
      "summary": "L\u0027article 3 des statuts a \u00E9t\u00E9 modifi\u00E9 pour ajouter les activit\u00E9s reprises sous le point 3 de l\u0027ordre du jour, incluant la consultance pharmaceutique, la gestion de probl\u00E9matiques techniques, la gestion d\u0027\u00E9quipes et divers services de transport et logistique.",
      "new_text": "La soci\u00E9t\u00E9 a pour objet, tant en Belgique qu\u2019\u00E0 l\u2019\u00E9tranger, pour compte propre ou compte de tiers ou en participation avec ceux-ci :\n- toutes les activit\u00E9s qui ont un rapport direct ou indirect avec les services de consultance et du management relatifs \u00E0 l\u2019industrie pharmaceutique et biotechnologique ;\n- toutes les activit\u00E9s qui ont un rapport direct ou indirect avec la gestion de probl\u00E9matiques li",
      "change_kind": "amended",
      "article_title": null,
      "article_number": "3"
    },
    {
      "summary": "L\u0027assembl\u00E9e g\u00E9n\u00E9rale conf\u00E8re tous pouvoirs \u00E0 l\u0027administrateur agissant s\u00E9par\u00E9ment, avec pouvoir de substitution, pour adapter les donn\u00E9es de la soci\u00E9t\u00E9 dans la Banque Carrefour des Entreprises et aupr\u00E8s de toutes autres administrations.",
      "new_text": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale conf\u00E8re tous pouvoirs \u00E0 l\u2019administrateur agissant s\u00E9par\u00E9ment, avec pouvoir de\nsubstitution, pour adapter les donn\u00E9es de la soci\u00E9t\u00E9 dans la Banque Carrefour des Entreprises et\naupr\u00E8s de toutes autres administrations aux d\u00E9cisions prises par la pr\u00E9sente assembl\u00E9e g\u00E9n\u00E9rale.\nA cette fin, le mandataire a le pouvoir de prendre tous engagements au nom de la soci\u00E9t\u00E9, de faire\ntoutes d",
      "change_kind": "added",
      "article_title": null,
      "article_number": "4"
    },
    {
      "summary": "La soci\u00E9t\u00E9 doit communiquer conform\u00E9ment \u00E0 l\u2019article 2:8 \u00A74 du Code des soci\u00E9t\u00E9s et des associations.",
      "new_text": "(\u2026)",
      "change_kind": "added",
      "article_title": null,
      "article_number": "5"
    }
  ],
  "governance_change": {
    "organ_kind_after": null,
    "organ_kind_before": null,
    "admin_delegated_added": [],
    "representation_rule_after": null,
    "co_signature_threshold_eur": null,
    "representation_rule_before": null
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Kim Lagae",
    "org_rep_person_name": null
  },
  "co_filed_documents": [
    "une exp\u00E9dition conforme de l\u2019acte",
    "le rapport",
    "une coordination des statuts"
  ],
  "shareholder_rights": null,
  "voorwerp_change_summary": "L\u0027objet de la soci\u00E9t\u00E9 a \u00E9t\u00E9 modifi\u00E9 pour y ajouter les activit\u00E9s reprises sous le point 3 de l\u0027ordre du jour, incluant la consultance pharmaceutique et biotechnologique, la gestion de probl\u00E9matiques techniques et scientifiques, la gestion d\u0027\u00E9quipes et de programmes, ainsi que divers services de transport, logistique, nettoyage, automobile et promotion immobili\u00E8re.",
  "capital_structure_change": null,
  "coordinated_text_lineage": null
}

{
  "events": [
    {
      "kind": "eenhoofdigheid_declaration",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_transfer",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": null,
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2024-07-05",
    "filing_date": "2024-06-27",
    "act_kind_objet": "Objet de l\u0027acte:"
  },
  "decision": {
    "body": "conseil_d_administration",
    "act_date": "2024-06-27",
    "unanimous": true,
    "under_authorized_capital": false,
    "underlying_resolution_date": "2024-02-07"
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0756.915.546",
    "name_full": "PHARMA AND BIOTECH LEADING CONSULT",
    "legal_form": "SRL",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "none",
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [],
  "shareholders_after": [
    {
      "kbo": null,
      "pct": null,
      "kind": "person",
      "name": "FERRAND Alexandre",
      "role": "g\u00E9rant_statutaire",
      "n_shares": null,
      "share_class": null
    },
    {
      "kbo": null,
      "pct": null,
      "kind": "person",
      "name": "Boutlelis Koaich",
      "role": "g\u00E9rant_statutaire",
      "n_shares": null,
      "share_class": null
    }
  ],
  "share_classes_after": []
}